Login
$NEO
$15.41 +$0.00 (0.0%) After hours

$NEO SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
28 Oct 2026 10-Q
28 Oct 2026 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (October 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third-quarter results for the period ended ...

05 Oct 2026 Form 4: Stone Warren, Pres & Chief Operating Officer

Received 17,562 shares by exercise or conversion · Gave up 6,911 shares to cover exercise price or tax

05 Oct 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

FORT MYERS, Fla.—NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession its Board of Dire...

03 Sep 2026 Form 4: Olivo Alicia C, EVP, GC & Business Development

Gave up 2,692 shares to cover exercise price or tax

25 Aug 2026 Form 4: Stone Warren, Pres & Chief Operating Officer

Received 28,106 shares by exercise or conversion · Gave up 11,060 shares to cover exercise price or tax

25 Aug 2026 S-8
14 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

06 Aug 2026 Form 4: Aunan Greg D, Chief Accounting Officer

Sold 20,000 shares ($321K)

04 Aug 2026 144
30 Jul 2026 144
30 Jul 2026 SCHEDULE 13G/A
30 Jul 2026 SCHEDULE 13G
28 Jul 2026 10-Q
28 Jul 2026 8-K: Results of Operations and Financial Condition

Fort Myers, Florida (July 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended Ju...

22 Jul 2026 8-K/A: Regulation FD Disclosure; Other Events

On July 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in Item 8.01 below.

20 Jul 2026 8-K: Regulation FD Disclosure; Other Events

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the De...

25 Jun 2026 Form 4: Starrett Carolyn S, Director

Granted 9,784 Stock Option (Right to Buy) · Granted 14,125 Restricted Stock Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support